MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis
Abnormal levels of microRNA (miR)-155, which regulate inflammation and immune responses, have been demonstrated in the colonic mucosa of patients with inflammatory bowel diseases (IBD), although its role in disease pathophysiology is unknown. We investigated the role of miR-155 in the acquisition an...
Gespeichert in:
Veröffentlicht in: | Experimental & molecular medicine 2015-05, Vol.47 (5), p.e164-e164 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e164 |
---|---|
container_issue | 5 |
container_start_page | e164 |
container_title | Experimental & molecular medicine |
container_volume | 47 |
creator | Pathak, Surajit Grillo, Alessia Rosaria Scarpa, Melania Brun, Paola D'Incà, Renata Nai, Laura Banerjee, Antara Cavallo, Donatella Barzon, Luisa Palù, Giorgio Sturniolo, Giacomo Carlo Buda, Andrea Castagliuolo, Ignazio |
description | Abnormal levels of microRNA (miR)-155, which regulate inflammation and immune responses, have been demonstrated in the colonic mucosa of patients with inflammatory bowel diseases (IBD), although its role in disease pathophysiology is unknown. We investigated the role of miR-155 in the acquisition and maintenance of an activated phenotype by intestinal myofibroblasts (IMF), a key cell population contributing to mucosal damage in IBD. IMF were isolated from colonic biopsies of healthy controls, ulcerative colitis (UC) and Crohn’s disease (CD) patients. MiR-155 in IMF was quantified by quantitative reverse transcription-PCR in basal condition and following exposure to TNF-α, interleukin (IL)-1β, lipopolysaccharide (LPS) or TGF-β1. The effects of miR-155 mimic or inhibitor transfection on cytokine release and suppressor of cytokine signaling 1 (SOCS1) expression were assessed by enzyme-linked immunosorbent assay and western blot, respectively. Regulation of the target gene SOCS1 expression by miR-155 was assessed using luciferase reporter construct. We found that miR-155 was significantly upregulated in UC as compared with control- and CD-derived IMF. Moreover, TNF-α and LPS, but not TGF-β1 and IL-1β, significantly increased miR-155 expression in IMF. Ectopic expression of miR-155 in control IMF augmented cytokines release, whereas it downregulated SOCS1 expression. MiR-155 knockdown in UC-IMF reduced cytokine production and enhanced SOCS1 expression. Luciferase reporter assay demonstrated that miR-155 directly targets SOCS1. Moreover, silencing of SOCS1 in control IMF significantly increased IL-6 and IL-8 release. In all, our data suggest that inflammatory mediators induce miR-155 expression in IMF of patients with UC. By downregulating the expression of SOCS1, miR-155 wires IMF inflammatory phenotype.
Ulcerative Colitis: The role of a microRNA
Increased levels of a microRNA in cells lining the colon of patients with ulcerative colitis suggest it plays a role in the condition. Ignazio Castagliuolo and colleagues at the University of Padova in Italy examined intestinal myofibroblast cells from patients with two forms of inflammatory bowel disease—ulcerative colitis and Crohn's disease. They compared these cells with those from healthy control subjects and found increased amounts of the microRNA miR-155 in ulcerative colitis but not in Crohn's disease. This particular micro RNA is known to regulate inflammation and immune responses. The researchers also found e |
doi_str_mv | 10.1038/emm.2015.21 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4454995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1683577435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-a0475607d37e9cb65d99bc66561debe587a3219f9c81bbc7700ed7a2d12fdd953</originalsourceid><addsrcrecordid>eNptkd1rFDEUxYMotlaffJc8CjprkkkmkxdBFr-gUrD6HDKZO7spyWRNMoX57826tVTw6V44P879OAi9pGRDSdu_gxA2jFCxYfQROmdEsabjtH38oD9Dz3K-IYQJLvlTdMaEUn3P5DlK39z3hgqBQxwXbwpkXPaA3Tx5E4IpMa34sIc5lvUAOE5VqUxxs_E4rHFyQ4qDN7lkPKy4mLSDKu7w9dX2mlYYL95CMsXdArbRu-Lyc_RkMj7Di7t6gX5--vhj-6W5vPr8dfvhsrG856UxhEvRETm2EpQdOjEqNdiuEx0dYQDRS9MyqiZlezoMVkpCYJSGjZRN46hEe4Hen3wPyxBgtDCXZLw-JBdMWnU0Tv-rzG6vd_FWcy64-mPw-s4gxV9LvVoHly14b2aIS9a061shJW-P6JsTalPMOcF0P4YSfUxJ15T0MSXNaKVfPdzsnv0bSwXenoBcpXkHSd_EJdWf5__6_QaVrJ9l</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1683577435</pqid></control><display><type>article</type><title>MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis</title><source>Nature Open Access</source><source>MEDLINE</source><source>KoreaMed Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Pathak, Surajit ; Grillo, Alessia Rosaria ; Scarpa, Melania ; Brun, Paola ; D'Incà, Renata ; Nai, Laura ; Banerjee, Antara ; Cavallo, Donatella ; Barzon, Luisa ; Palù, Giorgio ; Sturniolo, Giacomo Carlo ; Buda, Andrea ; Castagliuolo, Ignazio</creator><creatorcontrib>Pathak, Surajit ; Grillo, Alessia Rosaria ; Scarpa, Melania ; Brun, Paola ; D'Incà, Renata ; Nai, Laura ; Banerjee, Antara ; Cavallo, Donatella ; Barzon, Luisa ; Palù, Giorgio ; Sturniolo, Giacomo Carlo ; Buda, Andrea ; Castagliuolo, Ignazio</creatorcontrib><description>Abnormal levels of microRNA (miR)-155, which regulate inflammation and immune responses, have been demonstrated in the colonic mucosa of patients with inflammatory bowel diseases (IBD), although its role in disease pathophysiology is unknown. We investigated the role of miR-155 in the acquisition and maintenance of an activated phenotype by intestinal myofibroblasts (IMF), a key cell population contributing to mucosal damage in IBD. IMF were isolated from colonic biopsies of healthy controls, ulcerative colitis (UC) and Crohn’s disease (CD) patients. MiR-155 in IMF was quantified by quantitative reverse transcription-PCR in basal condition and following exposure to TNF-α, interleukin (IL)-1β, lipopolysaccharide (LPS) or TGF-β1. The effects of miR-155 mimic or inhibitor transfection on cytokine release and suppressor of cytokine signaling 1 (SOCS1) expression were assessed by enzyme-linked immunosorbent assay and western blot, respectively. Regulation of the target gene SOCS1 expression by miR-155 was assessed using luciferase reporter construct. We found that miR-155 was significantly upregulated in UC as compared with control- and CD-derived IMF. Moreover, TNF-α and LPS, but not TGF-β1 and IL-1β, significantly increased miR-155 expression in IMF. Ectopic expression of miR-155 in control IMF augmented cytokines release, whereas it downregulated SOCS1 expression. MiR-155 knockdown in UC-IMF reduced cytokine production and enhanced SOCS1 expression. Luciferase reporter assay demonstrated that miR-155 directly targets SOCS1. Moreover, silencing of SOCS1 in control IMF significantly increased IL-6 and IL-8 release. In all, our data suggest that inflammatory mediators induce miR-155 expression in IMF of patients with UC. By downregulating the expression of SOCS1, miR-155 wires IMF inflammatory phenotype.
Ulcerative Colitis: The role of a microRNA
Increased levels of a microRNA in cells lining the colon of patients with ulcerative colitis suggest it plays a role in the condition. Ignazio Castagliuolo and colleagues at the University of Padova in Italy examined intestinal myofibroblast cells from patients with two forms of inflammatory bowel disease—ulcerative colitis and Crohn's disease. They compared these cells with those from healthy control subjects and found increased amounts of the microRNA miR-155 in ulcerative colitis but not in Crohn's disease. This particular micro RNA is known to regulate inflammation and immune responses. The researchers also found evidence linking the RNA to the regulation of a specific gene that itself regulates the levels of signaling molecules called cytokines. The results suggest that drugs that inhibit miR-155 activity might offer a new approach for treatment.</description><identifier>ISSN: 2092-6413</identifier><identifier>ISSN: 1226-3613</identifier><identifier>EISSN: 2092-6413</identifier><identifier>DOI: 10.1038/emm.2015.21</identifier><identifier>PMID: 25998827</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/106 ; 13/109 ; 13/89 ; 38 ; 38/90 ; 631/250/256 ; Adult ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Cells, Cultured ; Colitis, Ulcerative - genetics ; Colitis, Ulcerative - immunology ; Colitis, Ulcerative - pathology ; Cytokines - immunology ; Female ; Gene Expression Regulation ; Humans ; Intestinal Mucosa - immunology ; Intestinal Mucosa - metabolism ; Intestinal Mucosa - pathology ; Male ; Medical Biochemistry ; MicroRNAs - genetics ; Middle Aged ; Molecular Medicine ; Myofibroblasts - immunology ; Myofibroblasts - metabolism ; Myofibroblasts - pathology ; Original ; original-article ; Stem Cells ; Suppressor of Cytokine Signaling 1 Protein ; Suppressor of Cytokine Signaling Proteins - genetics ; Tumor Necrosis Factor-alpha - immunology ; Up-Regulation ; Young Adult</subject><ispartof>Experimental & molecular medicine, 2015-05, Vol.47 (5), p.e164-e164</ispartof><rights>The Author(s) 2015</rights><rights>Copyright © 2015 KSBMB. 2015 KSBMB.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-a0475607d37e9cb65d99bc66561debe587a3219f9c81bbc7700ed7a2d12fdd953</citedby><cites>FETCH-LOGICAL-c484t-a0475607d37e9cb65d99bc66561debe587a3219f9c81bbc7700ed7a2d12fdd953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454995/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454995/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25998827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pathak, Surajit</creatorcontrib><creatorcontrib>Grillo, Alessia Rosaria</creatorcontrib><creatorcontrib>Scarpa, Melania</creatorcontrib><creatorcontrib>Brun, Paola</creatorcontrib><creatorcontrib>D'Incà, Renata</creatorcontrib><creatorcontrib>Nai, Laura</creatorcontrib><creatorcontrib>Banerjee, Antara</creatorcontrib><creatorcontrib>Cavallo, Donatella</creatorcontrib><creatorcontrib>Barzon, Luisa</creatorcontrib><creatorcontrib>Palù, Giorgio</creatorcontrib><creatorcontrib>Sturniolo, Giacomo Carlo</creatorcontrib><creatorcontrib>Buda, Andrea</creatorcontrib><creatorcontrib>Castagliuolo, Ignazio</creatorcontrib><title>MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis</title><title>Experimental & molecular medicine</title><addtitle>Exp Mol Med</addtitle><addtitle>Exp Mol Med</addtitle><description>Abnormal levels of microRNA (miR)-155, which regulate inflammation and immune responses, have been demonstrated in the colonic mucosa of patients with inflammatory bowel diseases (IBD), although its role in disease pathophysiology is unknown. We investigated the role of miR-155 in the acquisition and maintenance of an activated phenotype by intestinal myofibroblasts (IMF), a key cell population contributing to mucosal damage in IBD. IMF were isolated from colonic biopsies of healthy controls, ulcerative colitis (UC) and Crohn’s disease (CD) patients. MiR-155 in IMF was quantified by quantitative reverse transcription-PCR in basal condition and following exposure to TNF-α, interleukin (IL)-1β, lipopolysaccharide (LPS) or TGF-β1. The effects of miR-155 mimic or inhibitor transfection on cytokine release and suppressor of cytokine signaling 1 (SOCS1) expression were assessed by enzyme-linked immunosorbent assay and western blot, respectively. Regulation of the target gene SOCS1 expression by miR-155 was assessed using luciferase reporter construct. We found that miR-155 was significantly upregulated in UC as compared with control- and CD-derived IMF. Moreover, TNF-α and LPS, but not TGF-β1 and IL-1β, significantly increased miR-155 expression in IMF. Ectopic expression of miR-155 in control IMF augmented cytokines release, whereas it downregulated SOCS1 expression. MiR-155 knockdown in UC-IMF reduced cytokine production and enhanced SOCS1 expression. Luciferase reporter assay demonstrated that miR-155 directly targets SOCS1. Moreover, silencing of SOCS1 in control IMF significantly increased IL-6 and IL-8 release. In all, our data suggest that inflammatory mediators induce miR-155 expression in IMF of patients with UC. By downregulating the expression of SOCS1, miR-155 wires IMF inflammatory phenotype.
Ulcerative Colitis: The role of a microRNA
Increased levels of a microRNA in cells lining the colon of patients with ulcerative colitis suggest it plays a role in the condition. Ignazio Castagliuolo and colleagues at the University of Padova in Italy examined intestinal myofibroblast cells from patients with two forms of inflammatory bowel disease—ulcerative colitis and Crohn's disease. They compared these cells with those from healthy control subjects and found increased amounts of the microRNA miR-155 in ulcerative colitis but not in Crohn's disease. This particular micro RNA is known to regulate inflammation and immune responses. The researchers also found evidence linking the RNA to the regulation of a specific gene that itself regulates the levels of signaling molecules called cytokines. The results suggest that drugs that inhibit miR-155 activity might offer a new approach for treatment.</description><subject>13</subject><subject>13/106</subject><subject>13/109</subject><subject>13/89</subject><subject>38</subject><subject>38/90</subject><subject>631/250/256</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cells, Cultured</subject><subject>Colitis, Ulcerative - genetics</subject><subject>Colitis, Ulcerative - immunology</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Cytokines - immunology</subject><subject>Female</subject><subject>Gene Expression Regulation</subject><subject>Humans</subject><subject>Intestinal Mucosa - immunology</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Intestinal Mucosa - pathology</subject><subject>Male</subject><subject>Medical Biochemistry</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Myofibroblasts - immunology</subject><subject>Myofibroblasts - metabolism</subject><subject>Myofibroblasts - pathology</subject><subject>Original</subject><subject>original-article</subject><subject>Stem Cells</subject><subject>Suppressor of Cytokine Signaling 1 Protein</subject><subject>Suppressor of Cytokine Signaling Proteins - genetics</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><subject>Up-Regulation</subject><subject>Young Adult</subject><issn>2092-6413</issn><issn>1226-3613</issn><issn>2092-6413</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNptkd1rFDEUxYMotlaffJc8CjprkkkmkxdBFr-gUrD6HDKZO7spyWRNMoX57826tVTw6V44P879OAi9pGRDSdu_gxA2jFCxYfQROmdEsabjtH38oD9Dz3K-IYQJLvlTdMaEUn3P5DlK39z3hgqBQxwXbwpkXPaA3Tx5E4IpMa34sIc5lvUAOE5VqUxxs_E4rHFyQ4qDN7lkPKy4mLSDKu7w9dX2mlYYL95CMsXdArbRu-Lyc_RkMj7Di7t6gX5--vhj-6W5vPr8dfvhsrG856UxhEvRETm2EpQdOjEqNdiuEx0dYQDRS9MyqiZlezoMVkpCYJSGjZRN46hEe4Hen3wPyxBgtDCXZLw-JBdMWnU0Tv-rzG6vd_FWcy64-mPw-s4gxV9LvVoHly14b2aIS9a061shJW-P6JsTalPMOcF0P4YSfUxJ15T0MSXNaKVfPdzsnv0bSwXenoBcpXkHSd_EJdWf5__6_QaVrJ9l</recordid><startdate>20150522</startdate><enddate>20150522</enddate><creator>Pathak, Surajit</creator><creator>Grillo, Alessia Rosaria</creator><creator>Scarpa, Melania</creator><creator>Brun, Paola</creator><creator>D'Incà, Renata</creator><creator>Nai, Laura</creator><creator>Banerjee, Antara</creator><creator>Cavallo, Donatella</creator><creator>Barzon, Luisa</creator><creator>Palù, Giorgio</creator><creator>Sturniolo, Giacomo Carlo</creator><creator>Buda, Andrea</creator><creator>Castagliuolo, Ignazio</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150522</creationdate><title>MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis</title><author>Pathak, Surajit ; Grillo, Alessia Rosaria ; Scarpa, Melania ; Brun, Paola ; D'Incà, Renata ; Nai, Laura ; Banerjee, Antara ; Cavallo, Donatella ; Barzon, Luisa ; Palù, Giorgio ; Sturniolo, Giacomo Carlo ; Buda, Andrea ; Castagliuolo, Ignazio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-a0475607d37e9cb65d99bc66561debe587a3219f9c81bbc7700ed7a2d12fdd953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>13</topic><topic>13/106</topic><topic>13/109</topic><topic>13/89</topic><topic>38</topic><topic>38/90</topic><topic>631/250/256</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cells, Cultured</topic><topic>Colitis, Ulcerative - genetics</topic><topic>Colitis, Ulcerative - immunology</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Cytokines - immunology</topic><topic>Female</topic><topic>Gene Expression Regulation</topic><topic>Humans</topic><topic>Intestinal Mucosa - immunology</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Intestinal Mucosa - pathology</topic><topic>Male</topic><topic>Medical Biochemistry</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Myofibroblasts - immunology</topic><topic>Myofibroblasts - metabolism</topic><topic>Myofibroblasts - pathology</topic><topic>Original</topic><topic>original-article</topic><topic>Stem Cells</topic><topic>Suppressor of Cytokine Signaling 1 Protein</topic><topic>Suppressor of Cytokine Signaling Proteins - genetics</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><topic>Up-Regulation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pathak, Surajit</creatorcontrib><creatorcontrib>Grillo, Alessia Rosaria</creatorcontrib><creatorcontrib>Scarpa, Melania</creatorcontrib><creatorcontrib>Brun, Paola</creatorcontrib><creatorcontrib>D'Incà, Renata</creatorcontrib><creatorcontrib>Nai, Laura</creatorcontrib><creatorcontrib>Banerjee, Antara</creatorcontrib><creatorcontrib>Cavallo, Donatella</creatorcontrib><creatorcontrib>Barzon, Luisa</creatorcontrib><creatorcontrib>Palù, Giorgio</creatorcontrib><creatorcontrib>Sturniolo, Giacomo Carlo</creatorcontrib><creatorcontrib>Buda, Andrea</creatorcontrib><creatorcontrib>Castagliuolo, Ignazio</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental & molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pathak, Surajit</au><au>Grillo, Alessia Rosaria</au><au>Scarpa, Melania</au><au>Brun, Paola</au><au>D'Incà, Renata</au><au>Nai, Laura</au><au>Banerjee, Antara</au><au>Cavallo, Donatella</au><au>Barzon, Luisa</au><au>Palù, Giorgio</au><au>Sturniolo, Giacomo Carlo</au><au>Buda, Andrea</au><au>Castagliuolo, Ignazio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis</atitle><jtitle>Experimental & molecular medicine</jtitle><stitle>Exp Mol Med</stitle><addtitle>Exp Mol Med</addtitle><date>2015-05-22</date><risdate>2015</risdate><volume>47</volume><issue>5</issue><spage>e164</spage><epage>e164</epage><pages>e164-e164</pages><issn>2092-6413</issn><issn>1226-3613</issn><eissn>2092-6413</eissn><abstract>Abnormal levels of microRNA (miR)-155, which regulate inflammation and immune responses, have been demonstrated in the colonic mucosa of patients with inflammatory bowel diseases (IBD), although its role in disease pathophysiology is unknown. We investigated the role of miR-155 in the acquisition and maintenance of an activated phenotype by intestinal myofibroblasts (IMF), a key cell population contributing to mucosal damage in IBD. IMF were isolated from colonic biopsies of healthy controls, ulcerative colitis (UC) and Crohn’s disease (CD) patients. MiR-155 in IMF was quantified by quantitative reverse transcription-PCR in basal condition and following exposure to TNF-α, interleukin (IL)-1β, lipopolysaccharide (LPS) or TGF-β1. The effects of miR-155 mimic or inhibitor transfection on cytokine release and suppressor of cytokine signaling 1 (SOCS1) expression were assessed by enzyme-linked immunosorbent assay and western blot, respectively. Regulation of the target gene SOCS1 expression by miR-155 was assessed using luciferase reporter construct. We found that miR-155 was significantly upregulated in UC as compared with control- and CD-derived IMF. Moreover, TNF-α and LPS, but not TGF-β1 and IL-1β, significantly increased miR-155 expression in IMF. Ectopic expression of miR-155 in control IMF augmented cytokines release, whereas it downregulated SOCS1 expression. MiR-155 knockdown in UC-IMF reduced cytokine production and enhanced SOCS1 expression. Luciferase reporter assay demonstrated that miR-155 directly targets SOCS1. Moreover, silencing of SOCS1 in control IMF significantly increased IL-6 and IL-8 release. In all, our data suggest that inflammatory mediators induce miR-155 expression in IMF of patients with UC. By downregulating the expression of SOCS1, miR-155 wires IMF inflammatory phenotype.
Ulcerative Colitis: The role of a microRNA
Increased levels of a microRNA in cells lining the colon of patients with ulcerative colitis suggest it plays a role in the condition. Ignazio Castagliuolo and colleagues at the University of Padova in Italy examined intestinal myofibroblast cells from patients with two forms of inflammatory bowel disease—ulcerative colitis and Crohn's disease. They compared these cells with those from healthy control subjects and found increased amounts of the microRNA miR-155 in ulcerative colitis but not in Crohn's disease. This particular micro RNA is known to regulate inflammation and immune responses. The researchers also found evidence linking the RNA to the regulation of a specific gene that itself regulates the levels of signaling molecules called cytokines. The results suggest that drugs that inhibit miR-155 activity might offer a new approach for treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25998827</pmid><doi>10.1038/emm.2015.21</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2092-6413 |
ispartof | Experimental & molecular medicine, 2015-05, Vol.47 (5), p.e164-e164 |
issn | 2092-6413 1226-3613 2092-6413 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4454995 |
source | Nature Open Access; MEDLINE; KoreaMed Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA/Free Journals; Free Full-Text Journals in Chemistry |
subjects | 13 13/106 13/109 13/89 38 38/90 631/250/256 Adult Aged Biomedical and Life Sciences Biomedicine Cells, Cultured Colitis, Ulcerative - genetics Colitis, Ulcerative - immunology Colitis, Ulcerative - pathology Cytokines - immunology Female Gene Expression Regulation Humans Intestinal Mucosa - immunology Intestinal Mucosa - metabolism Intestinal Mucosa - pathology Male Medical Biochemistry MicroRNAs - genetics Middle Aged Molecular Medicine Myofibroblasts - immunology Myofibroblasts - metabolism Myofibroblasts - pathology Original original-article Stem Cells Suppressor of Cytokine Signaling 1 Protein Suppressor of Cytokine Signaling Proteins - genetics Tumor Necrosis Factor-alpha - immunology Up-Regulation Young Adult |
title | MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T04%3A48%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MiR-155%20modulates%20the%20inflammatory%20phenotype%20of%20intestinal%20myofibroblasts%20by%20targeting%20SOCS1%20in%20ulcerative%20colitis&rft.jtitle=Experimental%20&%20molecular%20medicine&rft.au=Pathak,%20Surajit&rft.date=2015-05-22&rft.volume=47&rft.issue=5&rft.spage=e164&rft.epage=e164&rft.pages=e164-e164&rft.issn=2092-6413&rft.eissn=2092-6413&rft_id=info:doi/10.1038/emm.2015.21&rft_dat=%3Cproquest_pubme%3E1683577435%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1683577435&rft_id=info:pmid/25998827&rfr_iscdi=true |